Extended Data Fig. 2: Ferroptosis inducer and DC efferocytosis.
From: Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes
a, Phagocytosis of E. coli bioparticles by dendritic cells measured at different time points with or without erastin treatment. Data are expressed as mean ± SD with n = 2 per condition. b, Ferroptosis inducer ML-162 does not enhance efferocytosis by dendritic cells. Live-cell imaging data are expressed as mean ± SEM (n = 3, DMSO and CytoD; n = 4, ML-162; n = 6, Erastin). c, Kinetics of efferocytosis by dendritic cells treated with antioxidant, Ferrostatin-1, erastin alone, or erastin + Ferrostatin-1 (n = 4 per condition, data are representative of two independent experiments). d, Measurement of glutathione levels in dendritic cells treated with erastin (n = 3 per condition, *** P < 0.001; via unpaired two-tailed t-test). e, Assessment of erastin drug cytotoxicity in dendritic cells by measuring Sytox Green fluorescence. Data are expressed as mean ± SD with n = 2 per condition. f, Measurement of lipid peroxidation and ROS (via C11-BODIPY and dihydrorhodamine 123 probes, respectively) in dendritic cells treated with ferroptosis inducers (n = 3 per condition). Results are expressed as fold change (FC). g, Direct comparison of kinetics of efferocytosis by dendritic cells treated with glutamate or erastin (n = 4, Glutamate and Erastin; n = 8, DMSO). h, Kinetics of efferocytosis after NAC, erastin alone or erastin + NAC treatment. DMSO was used as a vehicle control (n = 7, per condition). All live-cell imaging data (b, c, g, h) are expressed as mean ± SEM, * P < 0.05 *** P < 0.001; ****P < 0.0001; One-way ANOVA with Tukey’s multiple comparisons test. ns: non-significant.
